QURE
uniQure N.V.
NASDAQ · Healthcare · Biotechnology · NL
$44.50
−0.80%0
Insider buys (3m)
35
Insider sells (3m)
-$16.7M
Net value (3m)
+67.9%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Jul 7, 2026 | Kapusta Matthew C · director, officer: CEO, Managing Director | Sale | 4,282 | $45 |
| Jul 7, 2026 | Kapusta Matthew C · director, officer: CEO, Managing Director | Sale | 7,600 | $46 |
| Jul 7, 2026 | Kapusta Matthew C · director, officer: CEO, Managing Director | M-Exempt | 21,082 | $19 |
| Jul 7, 2026 | Kapusta Matthew C · director, officer: CEO, Managing Director | Sale | 9,200 | $44 |
| Jul 2, 2026 | Kaye Jack · director | M-Exempt | 4,107 | $37 |
| Jul 2, 2026 | Abi-Saab Walid · officer: Chief Medical Officer | Sale | 10,000 | $46 |
| Jul 2, 2026 | Abi-Saab Walid · officer: Chief Medical Officer | M-Exempt | 10,000 | $5.59 |
| Jul 2, 2026 | Abi-Saab Walid · officer: Chief Medical Officer | Sale | 20,000 | $46 |
| Jul 2, 2026 | Kaye Jack · director | Sale | 4,107 | $46 |
| Jul 2, 2026 | Kaye Jack · director | M-Exempt | 17,060 | $20 |
| Jul 2, 2026 | Kaye Jack · director | Sale | 17,060 | $46 |
| Jun 30, 2026 | Abi-Saab Walid · officer: Chief Medical Officer | Sale | 1,434 | $47 |
| Jun 26, 2026 | Kapusta Matthew C · director, officer: CEO, Managing Director | Sale | 6,696 | $50 |
| Jun 26, 2026 | Kapusta Matthew C · director, officer: CEO, Managing Director | M-Exempt | 4,128 | $32 |
| Jun 26, 2026 | Kapusta Matthew C · director, officer: CEO, Managing Director | Sale | 28,716 | $50 |
| Jun 26, 2026 | Kapusta Matthew C · director, officer: CEO, Managing Director | M-Exempt | 28,716 | $32 |
| Jun 22, 2026 | Kapusta Matthew C · director, officer: CEO, Managing Director | Sale | 4,656 | $50 |
| Jun 22, 2026 | Kapusta Matthew C · director, officer: CEO, Managing Director | Sale | 11,585 | $49 |
| Jun 22, 2026 | Balachandran Madhavan · director | Sale | 4,700 | $44 |
| Jun 22, 2026 | Kapusta Matthew C · director, officer: CEO, Managing Director | M-Exempt | 62,581 | $19 |
| Jun 22, 2026 | Kapusta Matthew C · director, officer: CEO, Managing Director | M-Exempt | 4,656 | $32 |
| Jun 22, 2026 | Kapusta Matthew C · director, officer: CEO, Managing Director | Sale | 37,015 | $50 |
| Jun 22, 2026 | Kaye Jack · director | Sale | 5,295 | $43 |
| Jun 22, 2026 | Kaye Jack · director | M-Exempt | 5,295 | $32 |
| Jun 22, 2026 | Kapusta Matthew C · director, officer: CEO, Managing Director | Sale | 23,977 | $43 |
| Jun 22, 2026 | Balachandran Madhavan · director | M-Exempt | 6,390 | $19 |
| Jun 22, 2026 | Kapusta Matthew C · director, officer: CEO, Managing Director | Sale | 33,334 | $45 |
| Jun 22, 2026 | Kapusta Matthew C · director, officer: CEO, Managing Director | Sale | 32,581 | $45 |
| Jun 22, 2026 | Balachandran Madhavan · director | Sale | 1,690 | $43 |
| Jun 22, 2026 | Balachandran Madhavan · director | M-Exempt | 5,295 | $32 |
Institutional positioning
13F filings over the trailing two quarters
New 136Increased 169Reduced 131Sold out 52
| Filer | Action | Shares | Filed |
|---|---|---|---|
| Avoro Capital Advisors LLC | Increased | 6,727,777 | Aug 14, 2026 |
| AVORO CAPITAL ADVISORS LLC | Increased | 6,150,000 | Mar 16, 2026 |
| AVORO CAPITAL ADVISORS LLC | Reduced | 5,959,595 | May 15, 2026 |
| ABRDN PLC | Increased | 5,306,386 | Apr 29, 2026 |
| JPMORGAN CHASE & CO | Increased | 4,867,755 | Aug 12, 2026 |
| RTW INVESTMENTS, LP | Increased | 3,941,572 | Aug 14, 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | Reduced | 3,644,200 | May 15, 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | Reduced | 3,494,697 | Aug 14, 2026 |
| STATE STREET CORP | Increased | 2,903,825 | Aug 7, 2026 |
| Aberdeen Group plc | Reduced | 2,848,117 | Jul 31, 2026 |
| JPMORGAN CHASE & CO | Reduced | 2,837,466 | May 13, 2026 |
| NANTAHALA CAPITAL MANAGEMENT, LLC | Increased | 2,837,078 | May 15, 2026 |
| CITIGROUP INC | Increased | 2,811,485 | May 11, 2026 |
| TWO SIGMA INVESTMENTS, LP | Increased | 2,675,871 | May 15, 2026 |
| RTW INVESTMENTS, LP | Reduced | 2,586,356 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Jul 7, 2026